Dai composti ad azione duale a quelli a triplice azione

Considerazioni sullo sviluppo di una nuova classe di antidepressivi

Translated title of the contribution: From dual action compounds to triple reuptake inhibitors: Considerations on the development of a new class of antidepressants

Bernardo Dell'Osso, S. R. Bareggi, M. C. Palazzo, G. Camuri, S. Bortolussi, A. C. Altamura

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In the mid 80's, the introduction of the selective serotonin reuptake inhibitors (SSRI) has largely replaced the first-generation antidepressants - tricyclics (TCA) and inhibitors of the monoamine-oxidase (I-MAO) - molecules with proven antidepressant efficacy and characterized, however, by significant side-effects. The introduction of the SSRIs and dual action antidepressants including also the Serotonin Noradrenalin Reuptake Inhibitors (SNRI) and Noradrenalin Dopamine Reuptake Inhibitors (NDRI), allowed a more selective mechanism of action and a consequent better tolerability. Nevertheless, if the good profile of tolerability produced a better compliance to therapies, particularly in the mid- to long-term, the rates of remission had not substantially changed in comparison to first generation antidepressants, and a large part of patients shows partial response to such compounds. Even though in the last years the bio-pathogenesis of Major Depression has been related not only to monoaminergic deficit, but also to other neurotransmitters (i.e.: Glutamate), as well as to the involvement of the immune and endocrine systems and, ultimately, to impaired neuroplasticity, the development of antidepressant molecules blocking the reuptake of one or more neurotransmitters is widespread. In mis perspective, the recent development of triple reuptake inhibitors (blocking serotonin, norepinephrine and dopamine) in the treatment of Major Depression seems to be the natural consequence of the evolution of the most recent classes of antidepressants (SSRI, SNRI, NRI and NDRI) in order to realize compounds that conjugate a wide spectrum of action with selectivity and specificity. The purpose of the present review article is to offer an updated pharmacological and clinical perspective on the dual selective compounds and on the current development of new triple reuptake inhibitors antidepressants.

Original languageItalian
Pages (from-to)114-125
Number of pages12
JournalItalian Journal of Psychopathology
Volume16
Issue number1
Publication statusPublished - Mar 2010

Fingerprint

Antidepressive Agents
Dopamine Uptake Inhibitors
Serotonin Uptake Inhibitors
Neurotransmitter Agents
Norepinephrine
Neuronal Plasticity
Endocrine System
Monoamine Oxidase Inhibitors
Tricyclic Antidepressive Agents
Glutamic Acid
Immune System
Pharmacology
Therapeutics
Serotonin and Noradrenaline Reuptake Inhibitors

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Dai composti ad azione duale a quelli a triplice azione : Considerazioni sullo sviluppo di una nuova classe di antidepressivi. / Dell'Osso, Bernardo; Bareggi, S. R.; Palazzo, M. C.; Camuri, G.; Bortolussi, S.; Altamura, A. C.

In: Italian Journal of Psychopathology, Vol. 16, No. 1, 03.2010, p. 114-125.

Research output: Contribution to journalArticle

@article{d294195026994882bbba25f5a2e3a18d,
title = "Dai composti ad azione duale a quelli a triplice azione: Considerazioni sullo sviluppo di una nuova classe di antidepressivi",
abstract = "In the mid 80's, the introduction of the selective serotonin reuptake inhibitors (SSRI) has largely replaced the first-generation antidepressants - tricyclics (TCA) and inhibitors of the monoamine-oxidase (I-MAO) - molecules with proven antidepressant efficacy and characterized, however, by significant side-effects. The introduction of the SSRIs and dual action antidepressants including also the Serotonin Noradrenalin Reuptake Inhibitors (SNRI) and Noradrenalin Dopamine Reuptake Inhibitors (NDRI), allowed a more selective mechanism of action and a consequent better tolerability. Nevertheless, if the good profile of tolerability produced a better compliance to therapies, particularly in the mid- to long-term, the rates of remission had not substantially changed in comparison to first generation antidepressants, and a large part of patients shows partial response to such compounds. Even though in the last years the bio-pathogenesis of Major Depression has been related not only to monoaminergic deficit, but also to other neurotransmitters (i.e.: Glutamate), as well as to the involvement of the immune and endocrine systems and, ultimately, to impaired neuroplasticity, the development of antidepressant molecules blocking the reuptake of one or more neurotransmitters is widespread. In mis perspective, the recent development of triple reuptake inhibitors (blocking serotonin, norepinephrine and dopamine) in the treatment of Major Depression seems to be the natural consequence of the evolution of the most recent classes of antidepressants (SSRI, SNRI, NRI and NDRI) in order to realize compounds that conjugate a wide spectrum of action with selectivity and specificity. The purpose of the present review article is to offer an updated pharmacological and clinical perspective on the dual selective compounds and on the current development of new triple reuptake inhibitors antidepressants.",
keywords = "Antidepressants, Monoamine Oxidase Inhibitors (MAOI), Noradrenalin Dopamine Reuptake Inhibitors (NDRI), Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin Noradrenalin Reuptake Inhibitors (SNRI), Tricyclics (TCA), Triple Reuptake Inhibitors (TRI)",
author = "Bernardo Dell'Osso and Bareggi, {S. R.} and Palazzo, {M. C.} and G. Camuri and S. Bortolussi and Altamura, {A. C.}",
year = "2010",
month = "3",
language = "Italian",
volume = "16",
pages = "114--125",
journal = "Giornale Italiano di Psicopatologia",
issn = "1592-1107",
publisher = "Pacini Editore s.r.l.",
number = "1",

}

TY - JOUR

T1 - Dai composti ad azione duale a quelli a triplice azione

T2 - Considerazioni sullo sviluppo di una nuova classe di antidepressivi

AU - Dell'Osso, Bernardo

AU - Bareggi, S. R.

AU - Palazzo, M. C.

AU - Camuri, G.

AU - Bortolussi, S.

AU - Altamura, A. C.

PY - 2010/3

Y1 - 2010/3

N2 - In the mid 80's, the introduction of the selective serotonin reuptake inhibitors (SSRI) has largely replaced the first-generation antidepressants - tricyclics (TCA) and inhibitors of the monoamine-oxidase (I-MAO) - molecules with proven antidepressant efficacy and characterized, however, by significant side-effects. The introduction of the SSRIs and dual action antidepressants including also the Serotonin Noradrenalin Reuptake Inhibitors (SNRI) and Noradrenalin Dopamine Reuptake Inhibitors (NDRI), allowed a more selective mechanism of action and a consequent better tolerability. Nevertheless, if the good profile of tolerability produced a better compliance to therapies, particularly in the mid- to long-term, the rates of remission had not substantially changed in comparison to first generation antidepressants, and a large part of patients shows partial response to such compounds. Even though in the last years the bio-pathogenesis of Major Depression has been related not only to monoaminergic deficit, but also to other neurotransmitters (i.e.: Glutamate), as well as to the involvement of the immune and endocrine systems and, ultimately, to impaired neuroplasticity, the development of antidepressant molecules blocking the reuptake of one or more neurotransmitters is widespread. In mis perspective, the recent development of triple reuptake inhibitors (blocking serotonin, norepinephrine and dopamine) in the treatment of Major Depression seems to be the natural consequence of the evolution of the most recent classes of antidepressants (SSRI, SNRI, NRI and NDRI) in order to realize compounds that conjugate a wide spectrum of action with selectivity and specificity. The purpose of the present review article is to offer an updated pharmacological and clinical perspective on the dual selective compounds and on the current development of new triple reuptake inhibitors antidepressants.

AB - In the mid 80's, the introduction of the selective serotonin reuptake inhibitors (SSRI) has largely replaced the first-generation antidepressants - tricyclics (TCA) and inhibitors of the monoamine-oxidase (I-MAO) - molecules with proven antidepressant efficacy and characterized, however, by significant side-effects. The introduction of the SSRIs and dual action antidepressants including also the Serotonin Noradrenalin Reuptake Inhibitors (SNRI) and Noradrenalin Dopamine Reuptake Inhibitors (NDRI), allowed a more selective mechanism of action and a consequent better tolerability. Nevertheless, if the good profile of tolerability produced a better compliance to therapies, particularly in the mid- to long-term, the rates of remission had not substantially changed in comparison to first generation antidepressants, and a large part of patients shows partial response to such compounds. Even though in the last years the bio-pathogenesis of Major Depression has been related not only to monoaminergic deficit, but also to other neurotransmitters (i.e.: Glutamate), as well as to the involvement of the immune and endocrine systems and, ultimately, to impaired neuroplasticity, the development of antidepressant molecules blocking the reuptake of one or more neurotransmitters is widespread. In mis perspective, the recent development of triple reuptake inhibitors (blocking serotonin, norepinephrine and dopamine) in the treatment of Major Depression seems to be the natural consequence of the evolution of the most recent classes of antidepressants (SSRI, SNRI, NRI and NDRI) in order to realize compounds that conjugate a wide spectrum of action with selectivity and specificity. The purpose of the present review article is to offer an updated pharmacological and clinical perspective on the dual selective compounds and on the current development of new triple reuptake inhibitors antidepressants.

KW - Antidepressants

KW - Monoamine Oxidase Inhibitors (MAOI)

KW - Noradrenalin Dopamine Reuptake Inhibitors (NDRI)

KW - Selective Serotonin Reuptake Inhibitors (SSRI)

KW - Serotonin Noradrenalin Reuptake Inhibitors (SNRI)

KW - Tricyclics (TCA)

KW - Triple Reuptake Inhibitors (TRI)

UR - http://www.scopus.com/inward/record.url?scp=77952992086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952992086&partnerID=8YFLogxK

M3 - Articolo

VL - 16

SP - 114

EP - 125

JO - Giornale Italiano di Psicopatologia

JF - Giornale Italiano di Psicopatologia

SN - 1592-1107

IS - 1

ER -